神経芽腫の世界市場レポート 2025年

神経芽腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.7％で39億3,000万米ドルに成長します。予測期間に予測される成長は、政府助成金の増加、罹患率の上昇、早期発見の重視の高まり、遺伝子変異の有病率の増加、調査と理解の進歩などの要因に起因しています。この期間に予想される主な動向としては、特定の分子経路を標的とする薬剤の開発、非侵襲的イメージング技術の革新、遺伝子編集技術の進歩、個別化治療アプローチへの重点化、放射性標識化合物の開発などが挙げられます。

神経芽腫市場の成長は、小児がんの罹患率の上昇によって牽引されると予想されます。小児がんは、主に小児や青年が罹患するがん群を指し、脳、血液、骨などの臓器が標的となることが多く、特殊な治療法が必要とされます。このような小児がん患者の増加は、診断技術の進歩、意識の向上、環境暴露、遺伝的要因、医学研究の進歩など、いくつかの要因によるものです。神経芽腫の治療は、小児がんに対する標的療法を提供し、早期介入を可能にすることで、若年患者の再発リスクを低減し、予後を改善します。例えば、2024年5月、米国を拠点とする専門機関である米国がん協会は、米国で15歳未満の小児ががんと診断されるのは2024年には約9,620人になり、2023年の5,290人から増加すると予測しました。その結果、小児がんの罹患率の上昇が神経芽腫市場の成長を促進する主要因となっています。

神経芽腫市場の主要企業は、ヒト化抗GD2モノクローナル抗体など、がん細胞をより効果的かつ安全に標的にする革新的な治療介入の開発に注力しています。これらの抗体は、がん細胞上のGD2分子を特異的に標的とするように設計される一方、ヒト成分を組み込むことで免疫拒絶反応を最小限に抑えています。例えば、2023年8月、英国を拠点とする臨床段階の製薬会社であるルネッサンス・ファーマ社は、セント・ジュード小児研究病院からHu14.18K322A（Hu14.18）を導入したと発表しました。この抗体は、希少で攻撃性の高い小児がんである高リスク神経芽腫と新たに診断された小児がんの治療用にデザインされたものです。契約によると、ルネッサンス社は米国、カナダ、欧州、中国、日本、トルコを含む世界の主要市場でHu14.18を開発、製造、商品化する独占的権利を得た。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界神経芽腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の神経芽腫市場：成長率分析
• 世界の神経芽腫市場の実績：規模と成長, 2019-2024
• 世界の神経芽腫市場の予測：規模と成長, 2024-2029, 2034F
• 世界神経芽腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の神経芽腫市場製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• ワクチン
• その他の製品タイプ
• 世界の神経芽腫市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 免疫療法
• その他の治療の種類
• 世界の神経芽腫市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンライン
• オフライン
• 世界の神経芽腫市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 世界の神経芽腫市場錠剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口化学療法錠
• 標的治療錠剤
• 世界の神経芽腫市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫療法ワクチン
• 治療ワクチン
• 世界の神経芽腫市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射薬
• モノクローナル抗体
• 細胞治療製品

第7章 地域別・国別分析

• 世界の神経芽腫市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の神経芽腫市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 神経芽腫市場：競合情勢
• 神経芽腫市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Sartorius AG Overview, Products and Services, Strategy and Financial Analysis
  • Recordati S.p.A Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• United Therapeutics Corporation
• BeiGene Ltd.
• MacroGenics Inc.
• Y-mAbs Therapeutics Inc.
• RedHill Biopharma Ltd.
• Clarity Pharmaceuticals Ltd.
• EUSA Pharma（UK）Ltd.
• US WorldMeds LLC
• Healio Inc.
• Ascentage Pharma
• Laboratorio Elea Phoenix S.A
• Curis Inc.
• PersonGen BioTherapeutics（Suzhou）Co. Ltd.
• Essential Pharma S.A
• Cellectar Biosciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 神経芽腫市場2029：新たな機会を提供する国
• 神経芽腫市場2029：新たな機会を提供するセグメント
• 神経芽腫市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Neuroblastoma is a type of cancer that predominantly affects children, originating from immature nerve cells called neuroblasts. This cancer often develops in the adrenal glands, which sit atop the kidneys, but it can also occur in other regions of the abdomen, chest, neck, or pelvis. Symptoms associated with neuroblastoma may include abdominal pain, swelling, fatigue, and in some cases, bone pain or the presence of lumps.

The primary product types for treating neuroblastoma include tablets, vaccines, and others. Tablets are solid oral dosages containing active ingredients, binders, and fillers, used in the treatment of neuroblastoma to administer chemotherapy or targeted therapy drugs. Treatment options for neuroblastoma include chemotherapy, immunotherapy, and other approaches, which are distributed through various channels, both online and offline. These treatments are typically used in hospitals and clinics.

The neuroblastoma market research report is one of a series of new reports from The Business Research Company that provides neuroblastoma market statistics including the neuroblastoma industry global market size regional shares competitors with the neuroblastoma market share detailed neuroblastoma market segments market trends and opportunities and any further data you may need to thrive in the neuroblastoma industry. This neuroblastoma market research report delivers a complete perspective of everything you need with an in-depth analysis of the current and future scenarios of the industry.

The neuroblastoma market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth observed during the historic period can be attributed to factors such as the rising prevalence of neuroblastoma, increased research and development focused on pediatric neuroblastoma treatments, a higher incidence of childhood cancer, and growing government funding and support.

The neuroblastoma market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth projected for the forecast period can be attributed to factors such as rising government funding, a higher incidence of the disease, an increasing emphasis on early detection, a growing prevalence of genetic mutations, and advancements in research and understanding. Key trends expected during this period include the development of drugs targeting specific molecular pathways, innovations in non-invasive imaging technologies, progress in gene-editing technologies, a greater focus on personalized treatment approaches, and the development of radiolabeled compounds.

The growth of the neuroblastoma market is expected to be driven by the rising incidence of childhood cancer. Childhood cancer refers to a group of cancers that primarily affect children and adolescents, often targeting organs such as the brain, blood, and bones, and requiring specialized treatment methods. This increase in childhood cancer cases can be attributed to several factors, including advancements in diagnostic techniques, greater awareness, environmental exposures, genetic factors, and progress in medical research. Neuroblastoma treatments offer targeted therapies for childhood cancer, allowing for early intervention that reduces the risk of recurrence and improves the prognosis for young patients. For example, in May 2024, the American Cancer Society, a US-based professional organization, projected that around 9,620 children under the age of 15 in the United States would be diagnosed with cancer in 2024, up from 5,290 cases in 2023. As a result, the rising incidence of childhood cancer is a key factor driving the growth of the neuroblastoma market.

Leading companies in the neuroblastoma market are concentrating on developing innovative therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to more effectively and safely target cancer cells. These antibodies are engineered to specifically target the GD2 molecule on cancer cells while minimizing immune rejection by incorporating human components. For example, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced that it had in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children's Research Hospital. This antibody is designed for the treatment of newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. According to the agreement, Renaissance has obtained exclusive rights to develop, manufacture, and commercialize Hu14.18 in key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, completed the acquisition of Apeiron Biologics AG for $100 million. Through this acquisition, Ligand gains royalty rights to Qarziba and aims to enhance its commercial royalty portfolio by adding a high-value immunotherapy for high-risk neuroblastoma. This move is expected to drive growth by generating long-term, predictable revenue from a diverse range of key products. Apeiron Biologics AG, based in Austria, is a biotech company specializing in the development of immunotherapies for neuroblastoma.

Major players in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroblastoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Neuroblastoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuroblastoma market consists of revenues earned by entities by providing services such as diagnosis and imaging, oncology treatment, and stem cell transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroblastoma market also consists of sales of radiopharmaceuticals, monoclonal antibodies, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuroblastoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuroblastoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuroblastoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuroblastoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Types: Tablets; Vaccines; Other Product Types
• 2) By Treatment Type: Chemotherapy; Immunotherapy; Other Treatment Types
• 3) By Distribution Channel: Online; Offline
• 4) By End-User: Hospitals; Clinics
• Subsegments:
• 1) By Tablets: Oral Chemotherapy Tablets; Targeted Therapy Tablets
• 2) By Vaccines: Immunotherapy Vaccines; Therapeutic Vaccines
• 3) By Other Product Types: Injectable Drugs; Monoclonal Antibodies; Cell Therapy Products
• Companies Mentioned:Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Sartorius AG; Recordati S.p.A
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neuroblastoma Market Characteristics

3. Neuroblastoma Market Trends And Strategies

4. Neuroblastoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neuroblastoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neuroblastoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neuroblastoma Market Growth Rate Analysis
• 5.4. Global Neuroblastoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neuroblastoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neuroblastoma Total Addressable Market (TAM)

6. Neuroblastoma Market Segmentation

• 6.1. Global Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Vaccines
• Other Product Types
• 6.2. Global Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Other Treatment Types
• 6.3. Global Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online
• Offline
• 6.4. Global Neuroblastoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• 6.5. Global Neuroblastoma Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Chemotherapy Tablets
• Targeted Therapy Tablets
• 6.6. Global Neuroblastoma Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy Vaccines
• Therapeutic Vaccines
• 6.7. Global Neuroblastoma Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Drugs
• Monoclonal Antibodies
• Cell Therapy Products

7. Neuroblastoma Market Regional And Country Analysis

• 7.1. Global Neuroblastoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neuroblastoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuroblastoma Market

• 8.1. Asia-Pacific Neuroblastoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuroblastoma Market

• 9.1. China Neuroblastoma Market Overview
• 9.2. China Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuroblastoma Market

• 10.1. India Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuroblastoma Market

• 11.1. Japan Neuroblastoma Market Overview
• 11.2. Japan Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuroblastoma Market

• 12.1. Australia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuroblastoma Market

• 13.1. Indonesia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuroblastoma Market

• 14.1. South Korea Neuroblastoma Market Overview
• 14.2. South Korea Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuroblastoma Market

• 15.1. Western Europe Neuroblastoma Market Overview
• 15.2. Western Europe Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuroblastoma Market

• 16.1. UK Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuroblastoma Market

• 17.1. Germany Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuroblastoma Market

• 18.1. France Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuroblastoma Market

• 19.1. Italy Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuroblastoma Market

• 20.1. Spain Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuroblastoma Market

• 21.1. Eastern Europe Neuroblastoma Market Overview
• 21.2. Eastern Europe Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuroblastoma Market

• 22.1. Russia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuroblastoma Market

• 23.1. North America Neuroblastoma Market Overview
• 23.2. North America Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuroblastoma Market

• 24.1. USA Neuroblastoma Market Overview
• 24.2. USA Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuroblastoma Market

• 25.1. Canada Neuroblastoma Market Overview
• 25.2. Canada Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuroblastoma Market

• 26.1. South America Neuroblastoma Market Overview
• 26.2. South America Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuroblastoma Market

• 27.1. Brazil Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuroblastoma Market

• 28.1. Middle East Neuroblastoma Market Overview
• 28.2. Middle East Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuroblastoma Market

• 29.1. Africa Neuroblastoma Market Overview
• 29.2. Africa Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuroblastoma Market Competitive Landscape And Company Profiles

• 30.1. Neuroblastoma Market Competitive Landscape
• 30.2. Neuroblastoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sartorius AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Recordati S.p.A Overview, Products and Services, Strategy and Financial Analysis

31. Neuroblastoma Market Other Major And Innovative Companies

• 31.1. United Therapeutics Corporation
• 31.2. BeiGene Ltd.
• 31.3. MacroGenics Inc.
• 31.4. Y-mAbs Therapeutics Inc.
• 31.5. RedHill Biopharma Ltd.
• 31.6. Clarity Pharmaceuticals Ltd.
• 31.7. EUSA Pharma (UK) Ltd.
• 31.8. US WorldMeds LLC
• 31.9. Healio Inc.
• 31.10. Ascentage Pharma
• 31.11. Laboratorio Elea Phoenix S.A
• 31.12. Curis Inc.
• 31.13. PersonGen BioTherapeutics (Suzhou) Co. Ltd.
• 31.14. Essential Pharma S.A
• 31.15. Cellectar Biosciences Inc.

32. Global Neuroblastoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuroblastoma Market

34. Recent Developments In The Neuroblastoma Market

35. Neuroblastoma Market High Potential Countries, Segments and Strategies

• 35.1 Neuroblastoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neuroblastoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neuroblastoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer